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Why does Jack, and not Jill, break his crown? Sex
disparity in brain tumors
Tao Sun, Nicole M Warrington and Joshua B Rubin*
Abstract
It is often reported that brain tumors occur more frequently in males, and that males suffer a worse outcome from
brain tumors than females. If correct, these observations suggest that sex plays a fundamental role in brain tumor
biology. The following review of the literature regarding primary and metastatic brain tumors, reveals that brain
tumors do occur more frequently in males compared to females regardless of age, tumor histology, or region of
the world. Sexually dimorphic mechanisms that might control tumor cell biology, as well as immune and brain
microenvironmental responses to cancer, are explored as the basis for this sex disparity. Elucidating the
mechanisms by which sex chromosomes and sex hormones impact on brain tumorigenesis and progression will
advance our understanding of basic cancer biology and is likely to be essential for optimizing the care of brain
tumor patients.
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Review
Primary brain tumors, including both malignant (high-
grade) and benign (low-grade) tumors, are highly mor-
bid and life-threatening diseases, particularly as a func-
tion of tumor histology, tumor location, and patient age
[1-4]. For many common brain tumors, outcome has
not improved significantly over the past 25 years despite
enormous advancements in neuroimaging, neurosurgery,
molecular diagnostics and chemotherapy [5]. Thus,
much of current research focuses on those aspects of
tumor cell biology and patient characteristics that drive
tumorigenesis and resistance to therapy. In this regard,
the greater prevalence of primary and metastatic brain
tumors in males compared to females, regardless of age,
tumor histology and region of the world, strongly sug-
gests that sex is an important determinant of brain
tumor biology. Further evaluation of the molecular
mechanisms by which sex affects brain tumorigenesis
could have significant impact on our understanding of
tumorigenesis in the brain and our approaches to treat-
ment of males and females with brain tumors. In the
following, we review the epidemiology of parenchymal
brain tumors with an emphasis on the relationship
between sex and brain tumor incidence, and explore
sexually dimorphic mechanisms that could potentially
underlie this critical element of brain tumor biology.
Primary brain tumors occur more commonly in males
throughout the world
Cancer rates often exhibit geographical variation sugges-
tive of racial and environmental influences on tumori-
genesis [6-9]. To determine whether similar regional
and racial factors influence how sex correlates with
brain tumor incidence, we retrospectively reviewed 16
independent reports in which data regarding sex and
brain tumor histology was readily available [2,10-24]. A
clear predominance of brain tumors in males was evi-
dent in reports from 15 different countries on 6 conti-
nents in which the ratio of cases in males compared to
females ranged from > 1 to 3.5 for the major histological
subtypes of central nervous system (CNS) parenchymal
diseases including astrocytoma (AST), glioblastoma mul-
tiforme (GBM), medulloblastoma (MB), ependymoma
(EPD) and oligodendroglioma (OLG) (Figure 1). These
observations indicate that sex affects brain tumorigen-
esis through mechanisms that are likely to be indepen-
dent of race and regional differences in environmental
exposures.
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In contrast to the above, meningiomas are intracranial
tumors that occur more commonly in females than
males [25]. However, meningioma is a mesenchymal
tumor and not a tumor of the brain parenchyma.
Instead, it derives and is generally confined to the
meningeal membranes that cover the brain. While the
sex disparity in meningioma is fascinating and no doubt
important, the extra-axial nature of meningioma sepa-
rates it from the parenchymal brain tumors described
above and it will not be discussed further in this review.
Primary brain tumors occur more commonly in males
regardless of age
For some cancers, the actions of sex hormones can pro-
mote or suppress tumor progression. For example,
estrogens can promote receptor positive breast cancer
development [26] but reduce the risk of gastric cancer
[27]. Analysis of brain tumor rates in older men and
postmenopausal women, as well as in prepubertal
children suggests that sex-dependent differences in cir-
culating sex steroids alone cannot account for the dis-
parity in brain tumor rates in men and women. In Israel
and Australia, brain tumors occur more frequently in
males older than 65 than in postmenopausal women
(M/F ratio = 1.3) [16,18]. In Los Angeles County, Cali-
fornia, the overall GBM incidence increased in both
sexes between 1974 and 1999. A male predominance in
brain tumors was evident throughout this period, and
this sex disparity dramatically increased in individuals
older than 65 [28].
Brain tumors are the leading cause of cancer-related
mortality in children [29]. Childhood brain tumors and
adult brain tumors differ in many ways including intra-
cranial locations, histological subtypes, presentation and
outcome [30-34]. Even for the same histological sub-
types, children and adults can exhibit distinct molecular
foundations. For instance, medulloblastoma, the most
common malignant brain tumor of childhood, develops
USA
(Hess, et al. (2004))
Adult: GBM (1.36); OLG (1.36) 
(Kohler, et al. (2011))
Adult: GBM (1.58); OLG (1.36) 
Pediatric: MB (1.33); PA (1.1); GBM 
(1.42); OLG (1.12)
Canada (Tabori, et al. (2005))
Adolescent: MB (1.4)
Morocco (Karkouri, et al. (2010))
Pediatric: MB=1.2; GBM (1.5); 
OLG (3.5); EPD (3.5)
United Kingdom (Arora, et al. (2008))
Adult: MB (1.73); GBM (1.75); OLG(3.21); EPD(1.38)
Pediatric: MB(1.73); AST(1); OLG( 3.21); EPD(1.38)
Germany (Rickert, et al. (2001))
Pediatric: Overall (1.55)
France (Rigau, et al. (2011))
Adult: MB (1.39); GBM(1.46); OLG 
(1.31); EPD (1.3)
Italy (Giordana, et al. (1999))
Adolescent and adult: MB= 2.46
China (Zhou, et al. (2008))
Pediatric: MB=2.6; AST=1.3; 
EPD=1.3
Iran (Mehrazin, et al. (2006))
Adult and Pediatric: 
MB=1.85; GBM=2.0; 
OLG=1.46
Japan (Nomura, et al. (2011))
Adult and pediatric: GBM=1.25 ; 
OLG=1.25; EPD=1.11
Australia (Dobes, et al. (2010))
Elderly adult: Overall (1.31)
Brazil (Rosenberg, et al. (2005))
Pediatric: Overall (1.17); first 
2 years of life (2.15)
Israel (Kushiner, et al. 
(2011))
Adult: GBM (1.39)
Sweden (Lannering, et al. (2009))
Pediatric: MB=1.4; AST=1; 
EPD=1 
Pakistan (Ahmed, et al. (2007))
Pediatric: MB= 3; PA=3; GBM=2; 
EPD=3
Figure 1 Sex-based differences in the rates of primary brain tumor exist regardless of age or geographical location. Reports from
around the world describing the incidence of common brain tumors as a function of sex are identified and linked to their countries of origin.
Numbers shown in the parentheses are the sex ratio (male/female) of major primary brain tumor types extracted from 16 independent
publications from 15 countries, including all major continents and regions of the world (North America, South America, Europe, Middle East,
Africa, Asia and Oceania) except for Antarctica. Overall, these studies covered the period of 1974 to 2008, and the sex ratio (male/female) in
almost all major brain tumors including both malignant and benign tumors is greater than 1 with a range of 1 to approximately 3.5. See also
[2,10-24]. Abbreviations: AST = astrocytoma; EPD = ependymoma; GBM = glioblastoma (multiforme); Glioma, (NOS) = glioma, not otherwise
specified; MB = medulloblastoma; OLG = oligodendroglioma; PA = pilocytic astrocytoma.
Sun et al. Biology of Sex Differences 2012, 3:3
http://www.bsd-journal.com/content/3/1/3
Page 2 of 10
infrequently in adults and exhibits age-dependent mole-
cular signatures [35,36]. Similarly, GBM occurs in
infants, teenagers and adults with distinct molecular
mechanisms and outcomes [37,38]. Despite divergent
pathogenesis, male predominance in medulloblastoma
and GBM exists in both adult and pediatric populations,
even in individuals of less than 2 years [14] (Figure 1).
Thus, the influence of sex on brain tumorigenesis is
operative regardless of age and sexual maturity, suggest-
ing that it is not a consequence of the acute effects of
circulating sex hormones.
Secondary brain tumors (metastases) occur more
commonly in males regardless of the primary cancer type
As many as one-third of all adult cancer cases are com-
plicated by metastases to the brain [39-41]. Brain metas-
tases occur most frequently in lung cancer (48%) and
breast cancer (16.5%) followed by a spectrum of other
cancers including melanoma, at frequencies less than
10% [40]. A striking disparity in the rates of brain
metastases in male and female cancer patients is evident
in several large studies involving different primary can-
cers (Table 1). While rates of primary lung cancer are
nearly equivalent in men and women in the US (54%
male, (http://www.cdc.gov/cancer/lung/statistics/[42]),
between 58% and 83% of all lung-derived brain metas-
tases occur in male patients [43-47]. Similarly, the rates
of melanoma are higher among women (http://www.cdc.
gov/cancer/dcpc/research/articles/melanoma_supple-
ment.htm, [42]), yet between 58% and 64% of all mela-
noma-derived brain metastases occur in male patients
[48-50]. The sex disparity in brain metastases is evident
in tumors derived from different tissues, including those
arising from different germ layers such as lung cancer
(endoderm and mesodermal origins) and melanoma
(neuroectodermal origin), suggesting that it may involve
differences in non-cell autonomous effects on cancer
cell biology including sexual dimorphism in immune
function and the microenvironment of the male and
female brains.
While the frequency of brain metastases complicating
pediatric cancers is far less than in adult cancers, a
male-female difference is evident in germ cell tumor
(GCT) metastases to the brain with 13/15 reported
cases occurring in males [51]. This is particularly inter-
esting given the large disparity in the rates of primary
intracranial GCT in young boys and girls. While the
reported overall ratio for GCTs (germinoma and non-
Table 1 Sex dependent pattern of brain metastases (BM)
Study (year) Total BM BM (lung cancer) BM (melanoma) Survival
Lagerwaard et al. (1999):
Male 810 (75%) 601 (83%)
Female 269* (25%) 120 (17%)
Chao et al. (2006):
Male 687 (61%) 5.8 months
Female 443* (39%) 6.1 months
Videtic et al. (2009):
Male 487 (58%) 5.5 months
Female 348 (42%) 6.3 months
Arrieta et al. (2009):
Male 164 (56%)
Female 129 (44%)
Assouline et al. (2011):
Male 164 (78%)
Female 45* (22%)
Sampson et al. (1998):
Male 431 (64%)
Female 239 (36%)
Hofmann et al. (2007):
Male 77 (58%) 17 weeks
Female 56 (42%) 36 weeks
Raizer et al. (2008):
Male 217 (61%)
Female 138 (39%)
*The following number of breast cancer cases was subtracted from the total number of female brain metastasis cases: Lagerwaard (213), Chao (158), Assouline
(23).
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germinomatous tumors) in boys compared to girls
ranges from approximately 3 to as much as 13:1,
[52-54], regional variation within the brain is evident. In
all, 70% of male GCTs occur in the pineal region and
75% of female GCTs occur in the suprasellar region
[55-57]. Within the pineal region male tumors predomi-
nate, but in the suprasellar region the ratio of male to
female GCTs is more equivalent. The patterns of pri-
mary and metastatic CNS GCTs suggest that critical sex
and region-dependent interactions occur between GCTs
and the brain microenvironment.
Sexually dimorphic biology may underlie sex disparity in
brain tumors
Primary and metastatic brain tumors occur more fre-
quently in males compared to females regardless of
tumor type, age, race or region of the world. These
observations suggest the existence of sexually dimorphic
mechanisms that broadly impact on tumorigenesis and
tumor progression. In this section we will examine sex-
ual dimorphism in pathways that could regulate cancer
growth and metastasis.
At birth, the brains of human males are 7.8% larger
than those of females. The sex disparity in brain size is
maintained and increases throughout life, such that the
average adult male brain is approximately 11% larger
than the female brain [58,59]. These disparities are not
a consequence of the acute actions of circulating sex
hormones alone, and are instead the result of compo-
nents of sexual differentiation that are measureable from
the time of fertilization. By 2 days post fertilization,
male embryos have more cells than female embryos
[59,60]. This is well before gonadal differentiation at 8
weeks, and indicates that sex chromosome-based
mechanisms of growth regulation exist [60]. Among the
genes encoded on the × chromosome that could directly
impact growth are glucose-6 phosphate dehydrogenase
(G6PD), hypoxanthine phosphoribosyltransferase 1
(HPRT1) and X-linked inhibitor of apoptosis protein
(XIAP) [61]. By the blastocyst stage of human develop-
ment, measureable differences in the expression of these
proteins as well as in the autosomally encoded DNA
methyltransferases DNMT3 A and B are evident. Thus,
at the preimplantation stage of embryogenesis, signifi-
cant differences in both sex chromosome encoded gene
expression and in more global gene expression are
observed between male and female embryos [62-65].
In addition to differences in gene expression, male and
female embryos exhibit differences in physiology. Total
glucose metabolism in human male embryos is twice
that of females and male embryos exhibit higher pyru-
vate and glucose uptake and lactate production than
female embryos [62,63,66,67]. Female embryos exhibit
greater G6PD expression and activity and four times the
pentose phosphate pathway (PPP) activity as observed in
males [62,63,66,68]. Alterations in glucose metabolism
are required for cancerous growth, and glucose must be
shunted from energy production to biosynthetic path-
ways [69,70]. Cancer cells preferentially employ aerobic
glycolysis (the Warburg effect), a non-oxidative form of
glucose metabolism characterized by increased glucose
utilization and lactate production [71-73]. Whether dif-
ferences in glucose consumption, lactate production,
G6PD and PPP activity in males and females renders
them more or less susceptible to oncogenic transforma-
tion remains to be determined.
Abnormal activation of the mitogen-activated protein
kinase (MAPK) pathway is a common mechanism for
dysregulated proliferation and survival in astrocytomas
and other cancers [74]. Greater MAPK pathway activa-
tion has been observed in male smooth muscle cells in
vitro [75] as well as in multiple areas of the male brain in
vivo [76,77]. Estrogens suppress MAPK activity in a sex-
dependent manner. In vitro, basal levels of activated
(phosphorylated) MAPK and extracellular-regulated
kinase (ERK) 1/2 were higher in female compared to
male astrocytes. However, female astrocytes exhibited
greater sensitivity to the MAPK pathway inhibitory
effects of estradiol than did male astrocytes [78,79]. Dif-
ferential sensitivity to the inhibitory effects of MAPK reg-
ulation by estrogens was correlated with downstream
processes such as proliferation and apoptosis. Further-
more, estrogen treatment increased apoptosis in female
cells to a greater degree than in male cells and decreased
the percentage of female, but not male, cells in S phase of
the cell cycle [78,79]. In the brain, estradiol is produced
from testosterone through the actions of aromatase. Aro-
matase expression is greater in female compared to male
astrocytes rendering female astrocytes more sensitive to
the effects of testosterone/estradiol than male astrocytes
[80]. Interestingly, in an intracranial xenograft model of
GBM, estradiol was determined to induce tumor cell
apoptosis and promote survival [81].
Among the important targets for estrogen regulation
of growth is the cyclic AMP responsive element binding
protein (CREB). CREB is a transcription factor that inte-
grates the growth promoting signals downstream of
multiple intracellular pathways such as the MAPK,
p38MAPK, phosphatidylinositol-3-kinase (PI3K)-AKT
and cyclic AMP (cAMP) pathways [82]. Estradiol pro-
motes CREB phosphorylation and interaction with
cAMP response elements within the promoter regions
of CREB target genes. The action of testosterone-derived
estradiol results in higher levels of phospho-CREB in
male astrocytes on the day of birth in sexually
dimorphic areas of the brain [78]. In addition, the
expression of several growth factors including trans-
forming growth factor (TGF) b2 is directly regulated by
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estradiol in astrocytes [78]. Importantly, TGFb2 is fre-
quently elevated in cancer cells [83]. Thus, the mechan-
isms of sexual differentiation share many similarities
with the mechanisms of oncogenesis (Figure 2). How
the process of sexual differentiation and sexually
dimorphic regulation of cellular growth relates to cancer
biology should be more fully explored.
Mechanisms of brain metastases
As first suggested by Paget [84] and demonstrated by
Hart and Fidler [85], patterns of solid tumor metastases
reflect both tumor cell intrinsic and target tissue micro-
environmental factors [86]. In this regard the prevalence
of metastases to the brain in male cancer patients is
relevant to this discussion.
Current models of metastasis describe a multistage
process in which primary tumor cells first gain access to
the lymphatics or circulatory system through mechan-
isms that resemble the normal epithelial to mesenchymal
transitions (EMT) that accompany the movement of
epithelial cells through the germ layers during early
development [87]. An EMT-like phenomenon, including
degradation of extracellular matrix and activation of
migratory pathways is also observed in cancer, and
appears to be essential for metastases [88]. Subsequent
establishment of secondary tumors involves avoidance of
negative and engagement of positive interactions with the
immune system [89], adhesion within target tissues and
growth of metastatic lesions through a series of recipro-
cal interactions between disseminated tumor cells and
the microenvironment of target tissues [90,91] (Figure 3).
Each stage of tumor metastasis involves mechanisms
that might function in a sexually dimorphic fashion and
Metabolism 
DNA Methylation 
Intracellular Signaling 
Differentiation 
Cell Migration 
Proliferation 
Apoptosis 
 
 
Sex chromosomes 
Perinatal Testosterone 
Puberty 
Acute Sex Hormone effects 
Genetic Events 
Microenvironmental Factors 
Mechanisms of  
Oncogenesis 
Mechanisms of  
Sexual Differentiation 
Figure 2 The mechanisms of sexual differentiation overlap
with the mechanisms of oncogenesis. The process of sexual
differentiation shares many fundamental features with oncogenesis,
including changes in DNA methylation, glucose metabolism, growth
factor signaling, cell migration, proliferation, apoptosis and
differentiation.
1. Tumor cell intrinsic 
mechanisms 
Primary Lung Cancer 
2. Crossing the blood brain barrier  
3. Conditioning the microenvironment  
Brain Metastasis 
4. Microenvironmental response  
Lung primary 
Brain metastasis 
Lung cancer cell 
Astrocyte
Key 
Figure 3 Potential mechanisms for disparate rates of brain
metastases in males and females. The process of metastasis to
the brain involves distinct steps dependent on different genes,
pathways and mechanisms. The initial stage (1) involves tumor cell
intrinsic mechanisms for the degradation of the extracellular matrix
and activation of migratory pathways. This process is often referred
to as epithelial to mesenchymal transition (EMT). Pictured is a lung
cancer primary tumor and the hematogenous dissemination of lung
cancer cells. For metastases to the brain, cells that gain access to
the circulatory system and avoid natural killer (NK) cell deletion
must cross the blood brain barrier (2). Once present in the brain
parenchyma, the lung cancer cells must condition the brain
microenvironment for continued growth (3). This process involves
secretion of cytokines that induce a microenvironmental response.
Pictured is the action of the lung cancer cells on an astrocyte. (4)
The activated astrocytes secrete cytokines and growth factors such
as interleukin (IL)-6 that promote tumor growth and protect
secondary tumors from the cytotoxic effects of chemotherapy.
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thereby contribute to the disparate rates of brain metas-
tases observed in multiple cancers. In non-small cell
lung cancer, periostin expression, a marker of EMT, was
significantly correlated with being male, suggesting that
males might possess greater tumor cell intrinsic poten-
tial for metastasis [92].
While activation of innate immune cells may promote
metastases, it is also likely that prior to the establish-
ment of secondary tumors, tumor cells are vulnerable to
immune surveillance and destruction. There are data to
suggest that natural killer (NK) cells play an especially
important role in this antimetastatic function [93]. NK
cell activity displays differential sensitivity to adrenergic
suppression in male and female rats, and this increases
the susceptibility of male rats to experimental lung
metastases. In a lung retention model of intravenously
introduced breast carcinoma cells (MADB106), male
rats displayed a greater sensitivity to metoproterenol
induced b adrenergic activation than female rats [94].
Prior to sexual maturation, differential sensitivity to
metoproterenol was not apparent. Further, ovariectomy
of female rats had no effect, while castration of male
rats abolished the metoproterenol effect in adult ani-
mals. These data suggest that sexually dimorphic
immune surveillance may impact on tumor metastases
in a circulating testosterone-dependent manner.
NK cell function and other components of the periph-
eral immune response may have limited impact on the
behavior of tumor cells once they gain access to the
CNS parenchyma. Instead, astrocytes and resident
microglia are the predominant components of the CNS
cellular immune response. Brain metastases are corre-
lated with significant astrocytic inflammatory reaction in
the brain. In response to inflammatory stimuli, astro-
cytes become ‘activated’ and in this state secrete a num-
ber of cytokines with potential growth promoting
properties including interleukin (IL)-1b, IL-3, IL-6,
tumor necrosis factor (TNF)a, TGFb, insulin-like
growth factor (IGF)-1 and platelet-derived growth factor
(PDGF) [95]. In experiments designed to identify astro-
cyte-derived factors essential for metastasis growth, IL-
1b, IL-6 and TNFa were all found to be capable of sti-
mulating HARA-B lung carcinoma growth [96]. Simi-
larly, coculture of astrocytes with lung or breast cancer
cells resulted in the upregulation of survival genes in
the cancer cells and the promotion of chemoresistance
[97]. Microenvironment-derived interleukin promotion
of tumor growth has also been seen with IL-1b stimula-
tion of melanoma [98-100] and IL-6 promotion of pri-
mary colon cancer and liver cancers [101,102].
The broad importance of cytokines, especially IL-1
and IL-6 to tumor growth is relevant to sex disparity in
brain metastases because astrocyte production of cyto-
kines is sexually dimorphic. While baseline expression
of IL-1b, IL-6, interferon-inducible protein (IP)-10 and
TNFa was similar in male and female astrocytes, a sig-
nificant disparity became apparent upon stimulation
with lipopolysaccharide (LPS). Under these infection
mimetic conditions, expression of IL-1b, IL-6 and TNFa
was significantly greater in male versus female astrocytes
[103]. Testosterone treatment of neonatal female mice
produced a male pattern of cytokine response in adult
animals suggesting that sexually dimorphic cytokine
production by astrocytes is a stable difference in func-
tion that is dependent upon the perinatal surge in tes-
tosterone. Similar disparity was observed in liver and
colon production of cytokines during primary tumori-
genesis of carcinoma [101,102]. In this case, the effects
of sex appeared to be mediated by the inhibitory effects
of estrogen on IL-6 signaling rather than testosterone
dependent sensitivity to immune suppression.
Further evidence for estrogen effects on tumor pro-
gression come from the study of sex on tumorigenesis
in a mouse model of medulloblastoma genesis as a con-
sequence of mutation in the sonic hedgehog (SHH)
receptor patched (PTC). In this model, more than 50%
of Ptc heterozygous mice develop preneoplastic lesions,
but bona fide malignancies develop in only 14% to 20%
[104,105]. Ovariectomized Ptc ± mice exhibited a higher
rate of tumor progression while estrogen treatment of
ovariectomized mice returned the tumor rate to baseline
[106]. In this case, the genesis of medulloblastoma is
driven by SHH pathway activation. Estrogen did not
alter the level of SHH pathway activation. This suggests
that estrogen might not exert its effect directly on
medulloblastoma cells, but rather might influence
microenvironmental function. This interpretation is sup-
ported by epidemiological data that suggests SHH-dri-
ven medulloblastoma do not occur at different rates in
prepubertal boys and girls [107]. Testing this hypothesis
would require examining the effects of sex and estrogen
on the promotion of SHH-independent tumor types.
Tumor recruitment and activation of astrocytes may
not only be important for the formation of metastases,
but also in the relative resistance of metastases to ther-
apy. In a model of experimental melanoma metastases,
astrocytes protected melanoma cells from the cytotoxic
effects of both p-glycoprotein sensitive and insensitive
agents [108]. The protection required direct contact
between tumor cells and astrocytes, gap junction com-
munication and appeared to be calcium dependent.
Thus, the disparate rates of brain metastases in males
and females appear to be a consequence of sexually
dimorphic tumor cell intrinsic mechanisms, as well as
disparity in immune cell and astrocyte function. Defin-
ing the sex-dependent mechanisms that regulate brain
metastases could advance efforts to (i) identify patients
at the highest risk for metastatic disease, (ii) prevent
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metastases from occurring, and (iii) improve brain
metastasis treatments.
Sex impacts on outcome from primary and secondary
brain tumors
The influence of sex on brain tumors extends beyond
tumorigenesis and includes outcome. It has been
demonstrated in both pediatric and adolescent groups
that males with medulloblastomas have a worse prog-
nosis than females [12,109,110]. Similarly females with
either low-grade or high-grade gliomas exhibit higher
survival compared to males [111-113]. The survival
advantage of being female also extends to brain metas-
tases where women with either lung cancer primaries or
melanoma exhibit longer survival compared to men
with the same condition [44,46,50].
Conclusions
The current failure of neuro-oncology to cure more
children and adults with brain tumors demands con-
tinued effort to understand the molecular basis for
brain tumorigenesis and to apply this knowledge to the
prevention and treatment of brain tumors. In this
regard, the significant impact that sex has on brain
tumor incidence and outcome suggests that important
oncogenic mechanisms will be revealed through the
illumination of how sex affects brain tumorigenesis. It
is likely that this will involve cell intrinsic mechanisms
regulating metabolism and growth, as well as funda-
mental mechanisms of cell migration, invasion,
immune activity and crosstalk between tumor cells and
their microenvironment. At the very least, these efforts
should help reduce the rates of brain tumors in males
to those in females and improve the outcome for
males to equal that of females. Beyond that, one can
hope that understanding sex disparity in brain tumors
is so fundamental to tumor biology that it will ulti-
mately result in reduced rates of brain tumors and
improved outcome for everyone.
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